The FDA has chosen Dr Vinay Prasad, a professor at UCSF, to lead its Center for Biologics Evaluation and Research.

OpenAI has reportedly met with officials from the U.S. Food and Drug Administration (FDA) to discuss the use of artificial ...

The U.S. Food and Drug Administration (FDA) has unveiled a historic initiative to implement artificial intelligence (AI) ...

Supposedly, the AI tool will speed up the FDA's drug review process by reducing the time its scientists have to spend doing ...

In a historic first for the agency, FDA Commissioner Martin A. Makary, M.D., M.P.H. announced an aggressive timeline to scale use of artificial intelligence ...

FDA will implement a secure generative AI system across all centers by June 30, aiming to streamline internal reviews and ...

A former critic of FDA and Pharma will now oversee the regulation of costly and complicated biologics like vaccines, gene therapies, and blood supply.

Peter Marks, the venerable head of the FDA’s Center for Biologics Evaluation and Research, has been forced out. In this ...

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.

High-ranking OpenAI employees have met with the FDA multiple times in recent weeks to discuss AI and a project called cderGPT ...

Vinay Prasad will be the next director of the FDA's Center for Biologics Evaluation and Research, after Peter Marks was ...